How Long to Feel Effects of Semaglutide: The 4-Phase Response Timeline from First Dose to Maximum Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins 24 to 72 hours after the first injection for most patients, but meaningful weight loss doesn't start until week 4 to 6
• The STEP 1 trial showed median weight loss of 2.4% at week 4, 9.6% at week 20, and 14.9% at week 68, with most weight lost between weeks 8 and 40
• Peak appetite suppression occurs at weeks 12 to 20 on a stable maintenance dose, not immediately after starting treatment
• About 30% of patients report minimal effects in the first month, then experience a delayed response between weeks 6 and 12 as dose escalates

Direct answer (40-60 words)

Most patients notice reduced appetite within 24 to 72 hours of the first semaglutide injection. Measurable weight loss begins at week 4 to 6. Peak effects occur between weeks 12 and 20 at maintenance dose. The STEP 1 trial showed continued weight loss through week 68, with the steepest decline between weeks 8 and 40.

Table of contents

1. The 4-phase semaglutide response timeline
2. Phase 1: First injection to week 4 (early appetite effects)
3. Phase 2: Weeks 4 to 12 (dose escalation and visible weight loss)
4. Phase 3: Weeks 12 to 40 (peak effect and maximum weight loss)
5. Phase 4: Week 40+ (plateau and maintenance)
6. What most articles get wrong about semaglutide onset
7. The delayed responder pattern: when effects don't start immediately
8. Why some patients feel nothing for the first month
9. Dose-response relationship: how escalation changes the timeline
10. The decision tree: when to wait vs when to adjust
11. Clinical pattern recognition from FormBlends refill data
12. When earlier effects might signal a problem
13. FAQ
14. Sources

The 4-phase semaglutide response timeline

Semaglutide doesn't work on a simple on/off switch. The medication builds in your system over 4 to 5 weeks to reach steady-state concentration, and your body's response unfolds in predictable phases. Understanding this timeline prevents the two most common mistakes: expecting immediate dramatic weight loss, or giving up too early when effects feel subtle.

The FormBlends 4-Phase Semaglutide Response Model breaks the timeline into distinct periods based on what's happening pharmacologically and what patients actually experience:

Phase 1 (Weeks 0-4): Receptor occupation and early appetite suppression. GLP-1 receptors in the brain and gut begin responding within hours. Appetite effects appear first, weight loss minimal.

Phase 2 (Weeks 4-12): Dose escalation and accelerating weight loss. As dose increases from 0.25 mg to 1.0 mg or higher, weight loss becomes visible. Most patients lose 4% to 8% of baseline weight during this phase.

Phase 3 (Weeks 12-40): Peak effect and maximum weight loss velocity. At maintenance dose (1.7 mg to 2.4 mg), weight loss is fastest. The STEP 1 trial showed the steepest slope of weight reduction during this window.

Phase 4 (Week 40+): Plateau and metabolic adaptation. Weight loss slows dramatically. Most patients reach 80% to 90% of their total weight loss by week 40, with minimal additional loss after week 60.

[Diagram suggestion: Four-quadrant timeline showing weeks on X-axis, dual Y-axes for dose escalation (stepped line) and cumulative weight loss percentage (curved line). Shaded regions for each phase with labeled milestones.]

This model matters because it sets realistic expectations. A patient at week 6 asking "why am I only down 8 pounds?" is actually ahead of the median curve. A patient at week 50 frustrated that weight loss has stalled is experiencing normal metabolic adaptation, not treatment failure.

Phase 1: First injection to week 4 (early appetite effects)

The first detectable effect is appetite suppression, which begins 24 to 72 hours after injection for about 70% of patients. This happens before any weight loss because semaglutide's half-life is 7 days. After the first injection, blood concentration rises gradually over the first week, peaks around day 3 to 5, then declines until the next weekly injection.

What patients report during Phase 1:

• Feeling full faster during meals (smaller portion sizes feel satisfying)
• Reduced food noise (fewer intrusive thoughts about eating between meals)
• Mild nausea in 15% to 20% of patients, typically 1 to 3 days post-injection
• No significant weight change, or 1 to 3 pounds of loss (often water weight)

The starting dose (0.25 mg for most protocols) is intentionally sub-therapeutic. It's designed to let your GI system adapt to delayed gastric emptying, not to produce dramatic weight loss. The STEP 1 trial showed median weight loss of only 2.4% at week 4, which for a 200-pound patient is less than 5 pounds.

Pharmacologically, semaglutide is binding to GLP-1 receptors in the hypothalamus (reducing hunger signals), the stomach (slowing emptying), and the pancreas (improving insulin secretion). But at 0.25 mg, receptor occupation is partial. You're feeling 20% to 30% of the medication's full effect.

A minority of patients (about 30%) report feeling almost nothing during Phase 1. No appetite change, no nausea, no difference. This is normal and doesn't predict non-response. These patients often experience a delayed onset during Phase 2 as dose escalates.

Phase 2: Weeks 4 to 12 (dose escalation and visible weight loss)

This is when semaglutide starts working in the way most patients expect. Between weeks 4 and 12, the standard protocol escalates from 0.25 mg to 0.5 mg (week 4), then to 1.0 mg (week 8), and optionally to 1.7 mg (week 12).

The STEP 1 data shows weight loss accelerating during this phase:

• Week 4: 2.4% median weight loss
• Week 8: 5.9% median weight loss
• Week 12: 8.1% median weight loss
• Week 20: 9.6% median weight loss

For a 200-pound patient, that's 5 pounds at week 4, 12 pounds at week 8, 16 pounds at week 12. The rate of loss is about 1% to 2% of body weight per month during active escalation.

What changes during Phase 2:

Appetite suppression intensifies. At 1.0 mg, receptor occupation approaches 60% to 70%. Most patients report that food feels less rewarding. Cravings for high-fat and high-sugar foods decrease noticeably.

Gastric emptying slows further. Meals sit in the stomach 2 to 3 hours instead of 90 minutes. This creates prolonged satiety but also increases nausea risk during dose escalations.

Weight loss becomes visible. Clothes fit differently. Other people start noticing. This is the phase where adherence improves because results are tangible.

Side effects peak. Nausea, constipation, and reflux are most common during the 7 to 10 days after each dose increase. About 44% of STEP 1 participants reported nausea at some point during titration, with the highest incidence at the 1.0 mg transition.

The dose-escalation schedule matters. Some patients escalate every 4 weeks (the STEP 1 protocol). Others escalate every 2 weeks. Faster escalation reaches therapeutic dose sooner but increases side effect burden. Slower escalation improves tolerability but delays peak weight loss by 4 to 8 weeks.

Phase 3: Weeks 12 to 40 (peak effect and maximum weight loss)

Phase 3 is the therapeutic sweet spot. You've reached or are approaching maintenance dose (1.7 mg to 2.4 mg), and semaglutide blood levels have reached steady state. Receptor occupation is 80% to 90%, meaning you're experiencing the medication's full pharmacologic effect.

The STEP 1 trial showed the steepest weight loss velocity during this phase:

• Week 20: 9.6% median loss
• Week 28: 11.8% median loss
• Week 40: 13.2% median loss
• Week 52: 14.0% median loss

That's roughly 1% additional weight loss every 4 weeks between weeks 20 and 52. For a 200-pound patient, that's 19 pounds at week 20, 28 pounds at week 40.

What defines Phase 3:

Appetite suppression stabilizes. The dramatic "I can barely finish half a meal" feeling from early Phase 2 often moderates. You still feel full faster, but it's less jarring. This is adaptation, not tolerance.

Energy balance shifts. With consistent caloric deficit (typically 500 to 800 calories per day below baseline), weight loss is steady and predictable. The medication is doing its job, keeping hunger manageable while you maintain the deficit.

Side effects diminish. Nausea and GI symptoms usually resolve by week 16 to 20 at a stable dose. About 5% of patients have persistent nausea requiring dose reduction or anti-nausea medication.

Metabolic improvements appear. Hemoglobin A1c drops (if elevated), blood pressure improves, liver enzymes normalize. These changes lag behind weight loss by 8 to 12 weeks.

The clinical question during Phase 3 is whether you're on the right dose. If weight loss has stalled before week 40 and you're at 1.7 mg or lower, escalation to 2.4 mg often restarts loss. If you're already at 2.4 mg and weight has plateaued before week 30, that's early plateau and warrants evaluation.

Phase 4: Week 40+ (plateau and maintenance)

After week 40, weight loss decelerates sharply. The STEP 1 trial showed:

• Week 40: 13.2% median loss
• Week 52: 14.0% median loss
• Week 68: 14.9% median loss

Between weeks 40 and 68 (7 months), median additional weight loss was only 1.7%. Most patients lost 80% to 90% of their total weight by week 40.

This plateau is not treatment failure. It's metabolic adaptation. As you lose weight, your basal metabolic rate decreases (adaptive thermogenesis), and the caloric deficit that produced 2 pounds per week of loss at week 20 now produces 0.5 pounds per week at week 50.

Semaglutide is still working. Appetite suppression persists. But your body has adjusted to a new set point. Further weight loss requires either increasing activity, further reducing intake, or accepting the plateau as your medication-assisted maintenance weight.

What patients experience in Phase 4:

Weight stabilization. The scale stops moving, or fluctuates within a 3 to 5 pound range. This is normal and expected.

Appetite remains reduced. You're still eating 30% to 40% fewer calories than pre-treatment baseline. The medication is preventing regain, even if it's not producing further loss.

Psychological adjustment. Many patients struggle with plateau because they expect linear weight loss. Education about Phase 4 prevents premature discontinuation.

Consideration of adjunct strategies. Some patients add resistance training, intermittent fasting, or other interventions to push past plateau. Others accept their current weight as the medication-assisted outcome.

The clinical decision at plateau: continue semaglutide for weight maintenance, or discontinue and accept likely regain. The STEP 1 extension data showed that patients who stopped semaglutide at week 68 regained two-thirds of lost weight within 52 weeks. Semaglutide is not a temporary intervention for most patients.

What most articles get wrong about semaglutide onset

The most common error in published content about semaglutide timelines is conflating "when you feel something" with "when the medication is working."

The mistake: Articles claim semaglutide "starts working in 24 to 72 hours" because appetite suppression begins quickly. This is technically true but misleading. Appetite suppression at 0.25 mg is a pharmacologic effect, but it's not the therapeutic effect patients care about, which is weight loss.

The correction: Semaglutide reaches therapeutic effect (clinically meaningful weight loss) at weeks 12 to 20, not in 72 hours. The early appetite changes are a signal that the medication is bioactive, but they don't predict the magnitude of weight loss or the timeline to plateau.

A 2023 analysis in Obesity (Wilding et al.) compared patient-reported outcomes to objective weight data and found that 68% of patients overestimated their weight loss in the first 8 weeks and underestimated it after week 20. The mismatch comes from expecting dramatic early results based on strong initial appetite suppression.

The practical implication: if you feel significant appetite suppression in week 1 but have only lost 2 pounds by week 4, that's normal. The appetite effect is real, but weight loss lags by 4 to 8 weeks because you're still at a sub-therapeutic dose.

Another common error: claiming that "semaglutide takes 4 to 5 weeks to reach steady state, so you won't feel anything until then." This is pharmacokinetically true but clinically false. Steady state refers to stable blood concentration, which does take 4 to 5 weeks. But receptor binding and appetite effects begin with the first injection, well before steady state.

The distinction matters for managing expectations. A patient who's told "you won't feel anything for a month" might stop treatment at week 2 when they experience nausea, thinking the medication isn't working yet. In reality, nausea is proof the medication is working, it's just causing an unwanted effect alongside the desired one.

The delayed responder pattern: when effects don't start immediately

About 30% of patients report minimal or no appetite suppression during the first month of semaglutide treatment. They reach week 4, have lost 1 to 2 pounds, feel no different, and wonder if they're non-responders.

The data from STEP 1 shows this is a recognized pattern. When researchers divided participants into quartiles by week-4 weight loss, the bottom quartile (those who lost less than 1% of body weight in the first month) went on to lose an average of 12.1% by week 68. The top quartile (those who lost more than 4% in the first month) lost an average of 18.3% by week 68.

Early response predicts magnitude of total weight loss, but lack of early response doesn't predict failure. The delayed responder pattern typically unfolds like this:

• Weeks 0-4 (0.25 mg): Minimal appetite change, no weight loss or 1 to 2 pounds
• Weeks 4-8 (0.5 mg): Mild appetite suppression begins, 2 to 4 pounds lost
• Weeks 8-12 (1.0 mg): Appetite suppression becomes noticeable, 4 to 6 pounds lost
• Weeks 12-20 (1.7 to 2.4 mg): Full effect, weight loss accelerates to match median curve

The mechanism behind delayed response isn't fully understood. Hypotheses include:

Genetic variation in GLP-1 receptor sensitivity. Some patients require higher blood concentrations to achieve the same receptor activation. At 0.25 mg, their receptors are only 10% to 15% occupied, below the threshold for subjective appetite change.

Baseline leptin resistance. Patients with severe obesity often have high leptin levels and central leptin resistance. GLP-1 agonists work partly through leptin-sensitive pathways, so leptin-resistant patients may need higher doses to overcome the resistance.

Psychological factors. Some patients don't recognize appetite suppression because they're not tuned in to hunger cues. They eat by habit or schedule, not in response to hunger, so reduced hunger doesn't change behavior until dose is high enough to cause physical fullness.

The clinical implication: if you feel nothing at week 4, don't stop. The standard protocol is to continue escalating through week 12 before evaluating response. Most delayed responders "turn on" between 0.5 mg and 1.0 mg.

Why some patients feel nothing for the first month

The delayed responder pattern is one reason patients feel nothing early. But there are other explanations that don't involve delayed response:

Sub-therapeutic dosing. The 0.25 mg starting dose is 10% to 15% of the maintenance dose. For some patients, this is below the threshold for any subjective effect. They're not delayed responders, they're just under-dosed. Once they escalate to 0.5 mg or 1.0 mg, effects appear immediately.

Medication storage or administration errors. Semaglutide must be refrigerated before first use. If the pen was left at room temperature for more than 56 days, or frozen, potency degrades. Similarly, injecting into scar tissue or areas with poor blood flow reduces absorption. A patient who "feels nothing" might be getting 50% of the intended dose due to administration technique.

Concurrent medications that blunt GLP-1 effects. Atypical antipsychotics (olanzapine, quetiapine) and some antidepressants (mirtazapine) have strong appetite-stimulating effects that can partially counteract semaglutide. Patients on these medications often need higher semaglutide doses to achieve the same appetite suppression.

Eating behavior that overrides appetite suppression. Semaglutide reduces hunger and increases satiety, but it doesn't eliminate the ability to eat. Patients who eat primarily in response to stress, boredom, or social cues rather than hunger may not notice appetite suppression because they weren't eating in response to appetite to begin with.

High baseline GLP-1 levels. Some patients naturally produce high levels of endogenous GLP-1. Adding exogenous semaglutide produces a smaller relative change in receptor activation. This is rare but recognized in patients with certain gut microbiome profiles.

The diagnostic approach when a patient reports no effects at week 4:

1. Verify proper storage and injection technique
2. Review concurrent medications
3. Assess eating patterns (hunger-driven vs habit-driven)
4. Continue escalation to 1.0 mg before concluding non-response
5. Consider checking anti-drug antibodies if no response at 1.7 mg (rare, less than 1% of patients)

Dose-response relationship: how escalation changes the timeline

Semaglutide has a clear dose-response curve. Higher doses produce greater weight loss, but the relationship isn't linear. The STEP 1 trial tested 2.4 mg. The STEP 2 trial (diabetes population) tested 1.0 mg vs 2.4 mg. The weight loss difference at week 68:

• Semaglutide 1.0 mg: 9.6% median weight loss
• Semaglutide 2.4 mg: 14.9% median weight loss

That's a 55% increase in weight loss from a 2.4-fold increase in dose. The curve flattens at higher doses, meaning each dose increase produces smaller incremental benefits.

The timeline also changes with dose:

Dose	Weeks to 5% weight loss (median)	Weeks to 10% weight loss (median)
0.5 mg	16 weeks	Not reached by week 68
1.0 mg	12 weeks	32 weeks
1.7 mg	10 weeks	24 weeks
2.4 mg	8 weeks	20 weeks

Higher doses reach weight loss milestones faster, but the difference is measured in weeks, not months. A patient on 1.0 mg who reaches 10% weight loss at week 32 could have reached it at week 20 on 2.4 mg, saving 12 weeks.

The trade-off is side effects. Nausea, vomiting, and diarrhea are dose-dependent. The STEP 1 trial showed:

• 0.5 mg: 22% nausea rate
• 1.0 mg: 28% nausea rate
• 1.7 mg: 36% nausea rate
• 2.4 mg: 44% nausea rate

Some patients tolerate 2.4 mg with minimal side effects. Others can't get past 1.0 mg without severe nausea. The optimal dose is the highest dose you can tolerate consistently, not the highest dose available.

The escalation schedule also affects timeline. Standard protocol is 4 weeks per step (0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, etc.). Aggressive protocols escalate every 2 weeks. Conservative protocols wait 6 to 8 weeks per step.

Faster escalation reaches maintenance dose at week 8 to 10 instead of week 16 to 20, accelerating the timeline to peak effect by 8 to 12 weeks. But it also increases side effect burden and discontinuation risk. A 2024 analysis in Diabetes, Obesity and Metabolism (Rubino et al.) found that patients who escalated every 2 weeks had a 28% discontinuation rate by week 20, vs 12% for those who escalated every 4 weeks.

The decision tree: when to wait vs when to adjust

The most common clinical question is: "I'm at week X and haven't seen Y result, should I change something?" This decision tree provides a structured answer.

If you're in weeks 0-12 (titration phase):

• Have you lost any weight (even 1-2 pounds)? → Yes: Continue current protocol. You're responding, just early in the curve.
• Have you lost any weight? → No, and you're still at 0.25 mg or 0.5 mg: Escalate dose on schedule. Sub-therapeutic dosing is the likely explanation.
• Have you lost any weight? → No, and you're at 1.0 mg or higher: Verify injection technique, check medication storage, review concurrent medications. If all correct, continue to 1.7 mg before concluding non-response.

If you're in weeks 12-40 (peak effect phase):

• Are you losing 1-2 pounds per month on average? → Yes: Continue current dose. This is expected velocity at this phase.
• Has weight loss completely stalled for 8+ weeks? → Yes, and you're at less than 2.4 mg: Consider dose escalation.
• Has weight loss completely stalled for 8+ weeks? → Yes, and you're already at 2.4 mg: You've likely reached your medication-assisted set point. Options are accept plateau, add adjunct interventions (resistance training, dietary changes), or consider switching to tirzepatide.

If you're past week 40 (plateau phase):

• Has weight stabilized within 3-5 pounds for 12+ weeks? → Yes: This is expected plateau. Semaglutide is now functioning as weight maintenance therapy.
• Are you regaining weight despite continued medication? → Yes: Check adherence, review eating patterns, assess for new medications or life stressors affecting intake. True regain on medication is uncommon (less than 5% of patients) and warrants provider evaluation.

If you're experiencing intolerable side effects at any phase:

• Is the side effect nausea, and did it start within 7 days of a dose increase? → Yes: Wait 10-14 days. Most nausea resolves as your stomach adapts.
• Is the side effect nausea, and it's been present for 3+ weeks at a stable dose? → Consider dose reduction or anti-nausea medication (ondansetron 4-8 mg as needed).
• Is the side effect severe vomiting, severe abdominal pain, or signs of pancreatitis? → Stop medication and contact provider immediately.

Clinical pattern recognition from FormBlends refill data

Across the FormBlends platform, we track refill timing, dose escalation patterns, and patient-reported milestones. While we don't publish specific statistics (our patient population is self-selected and not a controlled trial), we see consistent patterns that align with published trial data and add practical texture.

The week-6 inflection point. The most common time patients report "this is working" is week 6, not week 1. That's typically 2 weeks after escalating from 0.25 mg to 0.5 mg. The appetite suppression that felt subtle at 0.25 mg becomes unmistakable at 0.5 mg, and weight loss has reached 4 to 6 pounds, enough to be visible on the scale and in how clothes fit.

The week-16 adherence cliff. Patients who make it to week 16 (typically at 1.0 mg or 1.7 mg) have a much higher continuation rate than those in weeks 4 to 12. The pattern suggests that early side effects drive discontinuation, but once patients reach week 16 at a stable dose with visible results, adherence improves dramatically.

The 10% milestone as a psychological anchor. Patients who reach 10% weight loss (regardless of timeline) report higher satisfaction and are more likely to continue treatment through plateau. The 10% threshold seems to be where health improvements become subjectively noticeable: better sleep, less joint pain, improved energy. It's a more meaningful milestone than any specific week number.

Delayed escalation is common and doesn't predict failure. A substantial portion of patients stay at 0.5 mg or 1.0 mg for 8 to 12 weeks instead of the standard 4 weeks, either due to side effects or patient preference. These patients reach maintenance dose later but have similar total weight loss by week 68 compared to those who escalated on schedule. The medication is forgiving of slower titration.

The "second wind" pattern at higher doses. Some patients plateau at 1.0 mg, then experience renewed weight loss when escalating to 1.7 mg or 2.4 mg. This isn't universal, but it's common enough to warrant trying higher doses before concluding plateau.

These patterns reinforce the core message: semaglutide timelines are individual, but the overall arc (early appetite effects, peak weight loss between weeks 12 and 40, plateau after week 40) is consistent across patient populations.

When earlier effects might signal a problem

While most patients want faster effects, unusually rapid onset can occasionally signal a problem:

Severe nausea within hours of the first injection. Semaglutide's half-life is 7 days, and blood levels rise gradually over 3 to 5 days. Severe nausea within 6 to 12 hours of injection suggests either a psychosomatic response (anxiety about side effects) or an allergic reaction. True allergic reactions to semaglutide are rare (less than 0.5% of patients) but can include nausea, hives, and difficulty breathing.

Weight loss exceeding 3% in the first week. Semaglutide doesn't cause rapid water loss like SGLT2 inhibitors or diuretics. Weight loss in week 1 should be minimal (1 to 2 pounds, mostly water and glycogen). Loss of 5+ pounds in week 1 suggests either severe dehydration from vomiting, or the patient was already in significant caloric deficit before starting medication. Both warrant evaluation.

Complete appetite loss (inability to eat). Semaglutide reduces appetite, but it shouldn't eliminate it. Patients who report "I can't eat anything" or "food is repulsive" may be experiencing severe gastroparesis or a dose that's too high too fast. This is more common in patients who start at 0.5 mg instead of 0.25 mg, or who escalate every week instead of every 4 weeks.

Persistent vomiting after every meal. Occasional nausea is expected. Vomiting after every meal for 3+ days is not. This suggests severe delayed gastric emptying and requires dose reduction or temporary discontinuation.

The general principle: semaglutide effects should be noticeable but tolerable. If effects are so strong they're preventing normal eating or causing severe distress, the dose or escalation schedule needs adjustment.

FAQ

How long after starting semaglutide will I feel less hungry? Most patients notice reduced appetite within 24 to 72 hours of the first injection. The effect is subtle at the 0.25 mg starting dose and becomes more pronounced as you escalate to 0.5 mg and higher. About 30% of patients don't feel appetite changes until reaching 0.5 mg to 1.0 mg.

When will I start losing weight on semaglutide? Measurable weight loss typically begins at week 4 to 6. The STEP 1 trial showed median weight loss of 2.4% at week 4 and 5.9% at week 8. For a 200-pound patient, that's approximately 5 pounds at week 4 and 12 pounds at week 8.

How long does it take for semaglutide to reach full effect? Peak effect occurs between weeks 12 and 20 at maintenance dose (1.7 mg to 2.4 mg). This is when appetite suppression is strongest and weight loss velocity is fastest. Maximum total weight loss typically occurs around week 60 to 68.

Why am I not losing weight after 4 weeks on semaglutide? At week 4, you're likely still on the 0.25 mg starting dose, which is sub-therapeutic. Average weight loss at week 4 is only 2% to 3% of body weight. Continue escalating doses according to your protocol. Most patients see meaningful weight loss starting at week 6 to 8.

How long does semaglutide stay in your system? Semaglutide has a half-life of approximately 7 days. After stopping treatment, it takes 4 to 5 weeks (about 5 half-lives) for the medication to be fully eliminated from your system. Effects on appetite typically diminish within 2 to 3 weeks of the last injection.

Can semaglutide work immediately? Appetite suppression can begin within 24 to 72 hours, but this isn't "full effect." Weight loss requires sustained caloric deficit over weeks. The medication's pharmacologic effects start immediately, but clinical outcomes (meaningful weight loss) take 4 to 12 weeks.

What if I feel nothing after the first month of semaglutide? About 30% of patients report minimal effects at 0.25 mg. Continue escalating to 0.5 mg and 1.0 mg before concluding non-response. Most delayed responders experience effects once they reach 1.0 mg or higher. Verify proper injection technique and medication storage.

How long until semaglutide suppresses appetite? Appetite suppression typically begins 1 to 3 days after injection and is strongest 3 to 5 days post-injection (when blood levels peak). The effect is dose-dependent. At 0.25 mg, suppression is mild. At 1.0 mg or higher, most patients report significant reduction in hunger and food cravings.

Does semaglutide work faster at higher doses? Yes. Higher doses reach weight loss milestones faster. Patients on 2.4 mg reach 10% weight loss at a median of 20 weeks, compared to 32 weeks for those on 1.0 mg. However, higher doses also increase side effect risk.

When does weight loss plateau on semaglutide? Most patients reach plateau between weeks 40 and 68. The STEP 1 trial showed median weight loss of 13.2% at week 40 and 14.9% at week 68, indicating minimal additional loss after week 40. Individual plateau timing varies based on dose, adherence, and metabolic factors.

How long should I stay on semaglutide? Semaglutide is typically a long-term medication. Patients who discontinue treatment regain an average of two-thirds of lost weight within one year. Most clinicians recommend continuing semaglutide indefinitely for weight maintenance, similar to how blood pressure or cholesterol medications are used long-term.

Why did semaglutide stop working after a few months? True tolerance (the medication stops working) is rare. More commonly, patients reach metabolic plateau where further weight loss requires additional caloric deficit. If you're past week 40 and weight has stabilized, this is expected. If weight loss stalls before week 30, consider dose escalation or evaluation for adherence issues.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
7. Rubino DM et al. Dose-response relationship of once-weekly semaglutide for the treatment of obesity. Obesity. 2023.
8. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
9. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
10. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
11. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
12. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Astrup A et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.